Phase 3 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with uveal melanoma (a type of eye cancer) that has not spread to other parts of the body.
- People who are willing and able to give written consent before the trial begins, and who are able to follow all study requirements in the opinion of the doctor running the trial.
- People who are fully active or have only minor restrictions in physical activity (this is measured using a standard scale called ECOG, scored 0 or 1).
- People whose kidneys, liver, and other organs are functioning well enough to meet the trial's requirements.
Who may not be able to join:
- People who have already received treatment for their uveal melanoma.
- People who have uveal melanoma that has already spread to other parts of the body.
- People whose condition means the eye would need to be surgically removed regardless of how well any treatment works.
- People who have another ongoing eye disease that is getting worse and could interfere with regular vision assessments during the trial (confirm with trial site).
- People who have another type of cancer in addition to the uveal melanoma being studied in this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +1-855-433-2246
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Cohort 1: To demonstrate that the proportion of subjects with vision loss is lower for subjects in the Treatment Arm vs the Control Arm; Cohort 2: To demonstrate the ability to salvage the eye and prevent enucleation in the Treatment Arm
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.